Law360, New York (February 13, 2008, 12:00 AM ET) -- Novartis AG's oral fungal infection treatment Lamisil appears to put patients at risk of serious, and even life-threatening, liver, blood and skin problems, an Australian health regulator has reported.
The Australian Adverse Drug Reactions Advisory Committee said earlier this month that it had received 722 reports of harmful side effects from terbinafine, an oral version of the cream used to treat skin and nail fungal infections, sold under the brand name Lamisil. Three of those patients died from liver failure.
“ADRAC reminds prescribers that oral terbinafine...
Lamisil Poses Serious Health Risks: Report
To view the full article, take a free trial now.
